EU approves Novartis pain drug
Published by Live Search News: "Food and Drug Administration" November 7th, 2006 in Regulatory AffairsMorris County Daily Record - The Food and Drug Administration allowed Celebrex to stay on the market because there wasn’t enough data linking it with a higher risk of cardiovascular side effects. Pfizer had Celebrex sales of $537 million in the third quarter of this year. The …